|
US1548716A
(en)
|
1924-10-02 |
1925-08-04 |
Fournier Santiago Emilien |
Process for the manufacture of artificial freestone
|
|
US4235871A
(en)
|
1978-02-24 |
1980-11-25 |
Papahadjopoulos Demetrios P |
Method of encapsulating biologically active materials in lipid vesicles
|
|
US4501728A
(en)
|
1983-01-06 |
1985-02-26 |
Technology Unlimited, Inc. |
Masking of liposomes from RES recognition
|
|
US4837028A
(en)
|
1986-12-24 |
1989-06-06 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
|
DE69233013T2
(de)
|
1991-08-20 |
2004-03-04 |
The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer |
Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
|
|
US5252479A
(en)
|
1991-11-08 |
1993-10-12 |
Research Corporation Technologies, Inc. |
Safe vector for gene therapy
|
|
FR2688514A1
(fr)
|
1992-03-16 |
1993-09-17 |
Centre Nat Rech Scient |
Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
|
|
EP1024198A3
(en)
|
1992-12-03 |
2002-05-29 |
Genzyme Corporation |
Pseudo-adenoviral vectors for the gene therapy of haemophiliae
|
|
EP0705344B8
(en)
|
1993-06-24 |
2006-05-10 |
Advec Inc. |
Adenovirus vectors for gene therapy
|
|
AU687117B2
(en)
|
1993-10-25 |
1998-02-19 |
Canji, Inc. |
Recombinant adenoviral vector and methods of use
|
|
US5696234A
(en)
*
|
1994-08-01 |
1997-12-09 |
Schering Corporation |
Muteins of mammalian cytokine interleukin-13
|
|
US6682741B1
(en)
|
1998-06-10 |
2004-01-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
β2 microglobulin fusion proteins and high affinity variants
|
|
US7078387B1
(en)
|
1998-12-28 |
2006-07-18 |
Arch Development Corp. |
Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
|
|
US6287860B1
(en)
|
2000-01-20 |
2001-09-11 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of MEKK2 expression
|
|
CA2424158A1
(en)
|
2000-09-29 |
2002-04-11 |
The Scripps Research Institute |
Labeled peptides, and processes and intermediates useful for their preparation
|
|
US20040146520A1
(en)
*
|
2001-03-19 |
2004-07-29 |
Gavin Screaton |
Materials and methods relating to immune suppression
|
|
WO2002085923A2
(en)
|
2001-04-19 |
2002-10-31 |
The Scripps Research Institute |
In vivo incorporation of unnatural amino acids
|
|
US8895020B2
(en)
|
2002-04-19 |
2014-11-25 |
Washington University |
Single chain trimers and uses therefor
|
|
WO2005081716A2
(en)
|
2003-11-24 |
2005-09-09 |
The Johns Hopkins University |
DNA VACCINES TARGETING ANTIGENS OF THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-CoV)
|
|
GB0329146D0
(en)
|
2003-12-16 |
2004-01-21 |
Glaxosmithkline Biolog Sa |
Vaccine
|
|
US9163257B2
(en)
|
2005-06-20 |
2015-10-20 |
Cadila Healthcare Limited |
Expression vector and methods of producing high levels of proteins
|
|
US7521195B1
(en)
|
2005-07-21 |
2009-04-21 |
Celera Corporation |
Lung disease targets and uses thereof
|
|
US7855279B2
(en)
|
2005-09-27 |
2010-12-21 |
Amunix Operating, Inc. |
Unstructured recombinant polymers and uses thereof
|
|
AU2007223855B2
(en)
|
2006-03-06 |
2013-05-16 |
Amunix Operating Inc. |
Unstructured recombinant polymers and uses thereof
|
|
US8992937B2
(en)
|
2006-08-28 |
2015-03-31 |
Washington University |
Disulfide trap MHC class I molecules and uses therefor
|
|
JP2010536341A
(ja)
|
2007-08-15 |
2010-12-02 |
アムニクス， インコーポレイテッド |
生物学的に活性なポリペプチドの特性を改変するための組成物および方法
|
|
JP2012500855A
(ja)
|
2008-08-25 |
2012-01-12 |
アンプリミューン、インコーポレーテッド |
Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
|
|
EP2337795A2
(en)
|
2008-10-01 |
2011-06-29 |
Dako Denmark A/S |
Mhc multimers in cancer vaccines and immune monitoring
|
|
US20120021484A1
(en)
*
|
2008-10-22 |
2012-01-26 |
Biogen Idec Ma Inc. |
Recombinant FcRn and Variants Thereof for Purification of Fc-Containing Fusion Proteins
|
|
HUE027237T2
(en)
|
2008-11-30 |
2016-10-28 |
Immusant Inc |
Compositions and methods for treatment of celiac disease
|
|
ES2610356T3
(es)
|
2009-02-03 |
2017-04-27 |
Amunix Operating Inc. |
Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
|
|
WO2010096394A2
(en)
|
2009-02-17 |
2010-08-26 |
Redwood Biosciences, Inc. |
Aldehyde-tagged protein-based drug carriers and methods of use
|
|
WO2012037551A2
(en)
|
2010-09-17 |
2012-03-22 |
Irx Therapeutics, Inc. |
Primary cell-derived biologic and wt1 synthetic long peptide vaccine
|
|
US20120141537A1
(en)
|
2010-11-18 |
2012-06-07 |
Pease Larry R |
Enhancing t cell activation using altered mhc-peptide ligands
|
|
CA2860170C
(en)
*
|
2010-12-22 |
2022-06-14 |
The Board Of Trustees Of The Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
|
WO2012097333A2
(en)
|
2011-01-14 |
2012-07-19 |
Redwood Bioscience, Inc. |
Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
|
|
AU2012222833B2
(en)
|
2011-03-03 |
2017-03-16 |
Zymeworks Inc. |
Multivalent heteromultimer scaffold design and constructs
|
|
CA3205636A1
(en)
|
2011-04-20 |
2012-10-26 |
University Of Washington Through Its Center For Commercialization |
Beta-2 microglobulin-deficient cells
|
|
ES2893855T3
(es)
|
2011-08-11 |
2022-02-10 |
Ono Pharmaceutical Co |
Agente terapéutico para enfermedades autoinmunes que comprende agonista de PD-1
|
|
WO2013030620A2
(de)
|
2011-08-30 |
2013-03-07 |
Jacobs University Bremen Ggmbh |
Gen codiert für ein mhc-klasse-i-molekül, plasmid, expressionssystem protein, multimer, reagenz und kit zum analysieren einer t-zellen-frequenz
|
|
AU2013207669C1
(en)
|
2012-01-13 |
2018-05-31 |
Memorial Sloan Kettering Cancer Center |
Immunogenic WT-1 peptides and methods of use thereof
|
|
WO2013151665A2
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of proteins associated with human disease
|
|
EP2859017B1
(en)
|
2012-06-08 |
2019-02-20 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
|
WO2014004639A1
(en)
|
2012-06-26 |
2014-01-03 |
Sutro Biopharma, Inc. |
Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
|
|
EP3539563A1
(en)
|
2012-07-19 |
2019-09-18 |
Redwood Bioscience, Inc. |
Antibody specific for cd22 and methods of use thereof
|
|
US9310374B2
(en)
|
2012-11-16 |
2016-04-12 |
Redwood Bioscience, Inc. |
Hydrazinyl-indole compounds and methods for producing a conjugate
|
|
CA2894511C
(en)
|
2012-12-11 |
2021-12-07 |
Albert Einstein College Of Medicine Of Yeshiva University |
Methods for high throughput receptor:ligand identification
|
|
SG11201605632SA
(en)
|
2014-01-21 |
2016-08-30 |
Einstein Coll Med |
Cellular platform for rapid and comprehensive t-cell immunomonitoring
|
|
PT3134127T
(pt)
|
2014-04-25 |
2020-04-09 |
Rinat Neuroscience Corp |
Conjugados de anticorpo-fármaco com alta carga de fármaco
|
|
KR102486180B1
(ko)
|
2014-06-06 |
2023-01-11 |
레드우드 바이오사이언스 인코포레이티드 |
항-her2 항체-메이탄신 컨쥬게이트 및 이것의 사용 방법
|
|
WO2015195531A2
(en)
|
2014-06-18 |
2015-12-23 |
Albert Einstein College Of Medicine, Inc. |
Syntac polypeptides and uses thereof
|
|
WO2016154246A1
(en)
|
2015-03-23 |
2016-09-29 |
The Johns Hopkins University |
Hla-restricted epitopes encoded by somatically mutated genes
|
|
WO2016153572A1
(en)
|
2015-03-25 |
2016-09-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bispecific multivalent fusion proteins
|
|
SG11201708804WA
(en)
*
|
2015-05-07 |
2017-11-29 |
Agenus Inc |
Anti-ox40 antibodies and methods of use thereof
|
|
MX2018004875A
(es)
|
2015-10-22 |
2018-08-01 |
Juno Therapeutics Gmbh |
Metodos para cultivar celulas y kits y aparatos para ello.
|
|
WO2017151818A2
(en)
*
|
2016-03-02 |
2017-09-08 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
CA3014466A1
(en)
|
2016-03-03 |
2017-09-08 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
JP2019513373A
(ja)
|
2016-03-31 |
2019-05-30 |
ネオン セラピューティクス， インコーポレイテッド |
ネオ抗原およびその使用方法
|
|
JP7422480B2
(ja)
*
|
2016-05-04 |
2024-01-26 |
アムジエン・インコーポレーテツド |
制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質
|
|
CN109689096A
(zh)
|
2016-05-18 |
2019-04-26 |
阿尔伯特爱因斯坦医学院公司 |
变体pd-l1多肽、t细胞调节性多聚体多肽及其使用方法
|
|
WO2017201210A1
(en)
|
2016-05-18 |
2017-11-23 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
DE102016222109A1
(de)
|
2016-11-10 |
2018-05-17 |
Robert Bosch Gmbh |
Brennstoffzellensystem
|
|
ES2973548T3
(es)
|
2016-12-22 |
2024-06-20 |
Cue Biopharma Inc |
Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso
|
|
EP3565829A4
(en)
|
2017-01-09 |
2021-01-27 |
Cue Biopharma, Inc. |
T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF
|
|
US20200010528A1
(en)
|
2017-03-15 |
2020-01-09 |
Cue Biopharma, Inc. |
Methods for modulating an immune response
|
|
CN119409836A
(zh)
|
2017-03-17 |
2025-02-11 |
弗雷德哈钦森癌症中心 |
免疫调节融合蛋白及其用途
|
|
WO2019051126A1
(en)
|
2017-09-07 |
2019-03-14 |
Cue Biopharma, Inc. |
ANTIGEN PRESENTING POLYPEPTIDES COMPRISING CHEMICAL CONJUGATION SITES AND METHODS OF USE THEREOF
|
|
JP2020534352A
(ja)
|
2017-09-07 |
2020-11-26 |
キュー バイオファーマ，インコーポレーテッド |
コンジュゲーション部位を有するｔ細胞調節多量体ポリペプチド及びその使用方法
|
|
EP3678691A4
(en)
*
|
2017-09-07 |
2021-06-09 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
EP3678677A4
(en)
|
2017-09-07 |
2021-06-16 |
Cue Biopharma, Inc. |
Antigen-presenting polypeptides and methods of use thereof
|
|
CN111886241A
(zh)
|
2018-01-09 |
2020-11-03 |
库尔生物制药有限公司 |
多聚体t细胞调节多肽及其使用方法
|
|
IL277722B2
(en)
|
2018-04-02 |
2025-12-01 |
Pact Pharma Inc |
Peptide-mhc compacts
|
|
MX2021007479A
(es)
|
2018-12-19 |
2021-09-23 |
Cue Biopharma Inc |
Polipeptidos multimericos moduladores de linfocitos t y metodos de uso de estos.
|
|
WO2020132366A2
(en)
|
2018-12-19 |
2020-06-25 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
|
|
WO2020132136A1
(en)
|
2018-12-19 |
2020-06-25 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
EP3897690A4
(en)
|
2018-12-19 |
2022-09-28 |
Cue Biopharma, Inc. |
T LYMPHOCYTE MODULATOR MULTIMERIC POLYPEPTIDES HAVING CONJUGATION SITES AND METHODS OF USE THEREOF
|
|
WO2020132135A1
(en)
|
2018-12-19 |
2020-06-25 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
WO2020132365A2
(en)
|
2018-12-19 |
2020-06-25 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
|
|
TWI856047B
(zh)
|
2018-12-19 |
2024-09-21 |
美商信號生物製藥公司 |
多聚體ｔ細胞調節多肽及其使用方法
|
|
MX2021010089A
(es)
|
2019-02-20 |
2021-12-10 |
Rubius Therapeutics Inc |
Células eritroides diseñadas que incluyen polipéptidos que presentan antígeno cargable y métodos de uso.
|
|
EP3935079A4
(en)
|
2019-03-06 |
2023-03-22 |
Cue Biopharma, Inc. |
T-CELL MODULATING ANTIGEN PRESENT POLYPEPTIDES AND METHODS OF USE THEREOF
|
|
JP2022522405A
(ja)
|
2019-03-06 |
2022-04-19 |
キュー バイオファーマ， インコーポレイテッド |
Ｔ細胞調節多量体ポリペプチド及びその使用方法
|
|
KR20220015382A
(ko)
|
2019-05-29 |
2022-02-08 |
큐 바이오파마, 인크. |
다량체 t-세포 조절 폴리펩타이드 및 이의 사용 방법
|
|
JP2022536581A
(ja)
|
2019-06-19 |
2022-08-18 |
キュー バイオファーマ， インコーポレイテッド |
多量体ｔ細胞調節性ポリペプチド及びその使用方法
|
|
CA3146591A1
(en)
|
2019-09-20 |
2021-03-25 |
Ronald D. Seidel Iii |
T-cell modulatory polypeptides and methods of use thereof
|
|
CN120383671A
(zh)
|
2019-09-30 |
2025-07-29 |
阿迪马布有限责任公司 |
被工程化用于优先轻链配对的ch1结构域变体和包括所述ch1结构域变体的多特异性抗体
|
|
CA3146917A1
(en)
|
2019-10-23 |
2021-04-29 |
Anish SURI |
T-cell modulatory chimeric molecules and methods of use thereof
|
|
WO2021081232A1
(en)
|
2019-10-23 |
2021-04-29 |
Cue Biopharma, Inc. |
Modified cytotoxic t cells and methods of use thereof
|
|
WO2021195108A1
(en)
|
2020-03-24 |
2021-09-30 |
Cue Biopharma, Inc. |
T cell modulatory polypeptides and methods of use thereof
|
|
US20230117521A1
(en)
|
2020-03-25 |
2023-04-20 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
|
|
WO2021231376A2
(en)
|
2020-05-12 |
2021-11-18 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
WO2021242935A1
(en)
|
2020-05-26 |
2021-12-02 |
Cue Biopharma, Inc. |
Antigen presenting polypeptide complexes and methods of use thereof
|
|
IL299834A
(en)
|
2020-07-14 |
2023-03-01 |
Cue Biopharma Inc |
with binding sites and methods for using them T - cellular modulatory polypeptides
|
|
WO2022056014A1
(en)
|
2020-09-09 |
2022-03-17 |
Cue Biopharma, Inc. |
Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof
|
|
EP4210736A4
(en)
|
2020-09-09 |
2024-10-23 |
Cue Biopharma, Inc. |
MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS AND METHODS OF USE THEREOF
|
|
CA3174142A1
(en)
|
2020-11-06 |
2022-05-12 |
Ronald D. Seidel Iii |
T-cell modulatory polypeptides with conjugation sites and methods of use thereof
|
|
WO2022099157A1
(en)
|
2020-11-06 |
2022-05-12 |
Cue Biopharma, Inc. |
Antigen presenting polypeptide complexes and methods of use thereof
|
|
WO2022119958A1
(en)
|
2020-12-02 |
2022-06-09 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
WO2022197970A2
(en)
|
2021-03-19 |
2022-09-22 |
Cue Biopharma, Inc. |
T-cell modulatory polypeptides and methods of use thereof
|
|
AU2022238389A1
(en)
|
2021-03-19 |
2023-10-05 |
Cue Biopharma, Inc. |
T-cell modulatory polypeptides and methods of use thereof
|
|
WO2022226073A1
(en)
|
2021-04-21 |
2022-10-27 |
Cue Biopharma, Inc. |
Mhc class ii t-cell modulatory polypeptides and methods of use thereof
|
|
AU2022263441A1
(en)
|
2021-04-21 |
2023-11-09 |
Cue Biopharma, Inc. |
Antigen presenting polypeptide complexes bearing tgf-beta and methods of use thereof
|
|
AU2022261908A1
(en)
|
2021-04-21 |
2023-10-05 |
Cue Biopharma, Inc. |
Mhc class ii t-cell modulatory polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof
|
|
WO2023081718A1
(en)
|
2021-11-04 |
2023-05-11 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|